EC Number   |
Application |
Reference |
|---|
    1.14.13.9 | analysis |
comprehensive panel of biochemical and cell-based assays that use liquid chromatography/tandem mass spectrometry to quantify unlabeled kynurenine and 3-hydroxykynurenine and application to measure kynurenine monooxygenase inhibition in cell and tissue extracts, as well as cellular assays |
725567 |
| 1.14.13.9 | molecular biology |
development of a transformant selection system for Tribolium castaneum on the basis of mutant rescue |
658826 |
| 1.14.13.9 | medicine |
enzyme is a therapeutical target for treatment of Huntigton disease |
659985 |
| 1.14.13.9 | drug development |
enzyme KMO is an important drug target due to its role in regulating the levels of bioactive substances with contrasting effects. For treatment of central nervous related diseases, it is required that enzyme inhibitors should be both blood brain barrier permeable and should not cause hydrogen peroxide as a harmful side product. Molecular dynamics simulations and MM/GBSA calculations, overview |
765242 |
| 1.14.13.9 | drug development |
importance of KMO as a drug target in neurological disease, benefits of brain permeable inhibitors in modulating kynurenine pathway metabolites in the central nervous system teeating brain neurological diseases |
764034 |
| 1.14.13.9 | medicine |
importance of KMO as a drug target in neurological disease, benefits of brain permeable inhibitors in modulating kynurenine pathway metabolites in the central nervous system teeating brain neurological diseases. KMO inhibitors with brain permeability would be predicted to be more efficacious for treating neurodegenerative diseases than peripheral treatment, as inhibition of KMO in the CNS leads to increased neuroprotective KYNA levels as well as decreased levels of neurotoxic metabolites |
764034 |
| 1.14.13.9 | medicine |
inhibition of the enzyme shows benefit in neurodegenerative diseases such as Huntington's and Alzheimer's. It is a target for acute pancreatitis multiple organ dysfunction syndrome |
743342 |
| 1.14.13.9 | medicine |
inhibition of the enzyme shows benefit in neurodegenerative diseases such as Huntington's and Alzheimer's. It is a target for acute pancreatitis multiple organ dysfunction syndrome (AP-MODS) |
743342 |
| 1.14.13.9 | medicine |
KMO and its enzymatic product QUIN are potential broad-spectrum antiviral factor therapeutics against emerging pathogenic viruses |
765669 |
| 1.14.13.9 | drug development |
KMO has been identified as a therapeutic target for limiting neuronal damage from ischemia and specific diseases. The inhibition of KMO in vivo has synergistic neuroprotective effects that include elevation of the concentration of kynurenate, that both slows glutamate release and antagonizes NMDA receptors, reducing aberrant excitation. Inhibition of KMO also has the added benefit of halting the accumulation of specific neurotoxic and/or apoptotic metabolites, such as 3-hydroxy-L-kynurenine and quinolinic acid |
764027 |
